Myeloma Trial, Recruiting (NCT01137643)

Myeloma Trial, Recruiting NCT01137643 Sponsor: UNC Lineberger Comprehensive Cancer Center Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT01137643 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with a blood or immune system cancer or disorder, including: Acute myeloid leukemia, Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Chronic lymphoid leukemia, Non-Hodgkin lymphoma, Hodgkin lymphoma, Myelodysplastic syndromes, Myeloproliferative disorders, Multiple myeloma, Waldenstrom macroglobulinemia, Aplastic anemia, or any other condition that causes abnormal numbers or function of blood and immune system cells.
People who are being seen at the blood cancer or oncology clinics, the stem cell transplant clinic, or in hospital at the University of North Carolina Hospitals.

Who may not be able to join:

No specific exclusion criteria have been listed for this trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paul Armistead, MD, UNC Lineberger Comprehensive Cancer Center

Phone: (919) 843-6847

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT01137643

Sponsor: UNC Lineberger Comprehensive Cancer Center

Phase: Not Applicable

Status: Recruiting

Condition: Myeloma

Trial contact: (919) 843-6847

More information: https://clinicaltrials.gov/study/NCT01137643

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with a blood or immune system cancer or disorder, including: Acute myeloid leukemia, Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Chronic lymphoid leukemia, Non-Hodgkin lymphoma, Hodgkin lymphoma, Myelodysplastic syndromes, Myeloproliferative disorders, Multiple myeloma, Waldenstrom macroglobulinemia, Aplastic anemia, or any other condition that causes abnormal numbers or function of blood and immune system cells.
People who are being seen at the blood cancer or oncology clinics, the stem cell transplant clinic, or in hospital at the University of North Carolina Hospitals.

Who may not be able to join:

No specific exclusion criteria have been listed for this trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

UNC Lineberger Comprehensive Cancer Center

Registry

ClinicalTrials.gov

Start date

1 July 2009

Est. completion

1 July 2040

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies; Development of a centralized, quality-controlled, quality-assured facility for the procurement, processing, storage, and distribution of normal and malignant tissue specimens and corresponding blood specimens

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov